Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MAPT | P10636 | 1/20 | 0.49 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.47 |
| ▸ | CXCL8 | P10145 | 1/20 | 0.47 |
| ▸ | CES2 | O00748 | 1/20 | 0.44 |
| ▸ | CES1 | P23141 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | PPARG | P37231 | 1/20 | 0.44 |
| ▸ | PPARA | Q07869 | 1/20 | 0.44 |
| ▸ | GAA | P10253 | 1/20 | 0.44 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | NPC1 | O15118 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.41 |
| ▸ | MRGPRX4 | Q96LA9 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29585912 | 1.00 | FAAH (0.49) | FAAHALDH1A1SMN1; SMN2MAPTPARP10 | |
| SCHEMBL8499008 | 0.90 | FAAH (0.54) | FAAHALDH1A1SMN1; SMN2MAPTPARP10 | |
| SCHEMBL11602464 | 0.88 | FAAH (0.42) | FAAHALDH1A1SMN1; SMN2MAPTPARP10 | |
| SCHEMBL15454164 | 0.87 | HPGD (0.59) | FAAHALDH1A1SMN1; SMN2MAPTKMT2A | |
| SCHEMBL26622209 | 0.87 | FAAH (0.44) | FAAHALDH1A1SMN1; SMN2MAPTPARP10 | |
| SCHEMBL18697277 | 0.86 | FAAH (0.49) | FAAHALDH1A1SMN1; SMN2MAPTPARP10 | |
| SCHEMBL2940941 | 0.86 | FAAH (0.49) | FAAHALDH1A1SMN1; SMN2MAPTPARP10 | |
| SCHEMBL17720770 | 0.85 | FABP3 (0.48) | FAAHALDH1A1SMN1; SMN2MAPTCXCL8 | |
| SCHEMBL57244 | 0.84 | FAAH (0.51) | FAAHALDH1A1SMN1; SMN2MAPTPARP10 | |
| SCHEMBL6966435 | 0.84 | FAAH (0.47) | FAAHALDH1A1SMN1; SMN2MAPTPARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 92 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4255960-B1 | PROCESS FOR THE PREPARATION OF A POLYCARBONATE USING A HALOGENATED DIARYL CARBONATE | COVESTRO DEUTSCHLAND AG (DE) | 2025-10-08 | — | — | EP | claimed |
| EP-4255960-A1 | PROCESS FOR PREPARING A POLYCARBONATE USING A HALOGENATED DIARYL CARBONATE | Covestro Deutschland AG (DE) | 2023-10-11 | — | — | EP | claimed |
| WO-2023179324-A1 | ELECTROLYTIC SOLUTION CONTAINING FLUOROBENZENE CARBONATE, AND BATTERY COMPOSED OF ELECTROLYTIC SOLUTION | 香河昆仑新能源材料股份有限公司 | 2023-09-28 | — | — | WO | claimed |
| EP-4227293-A2 | CRYSTALLINE FORMS OF 1-(ACYLOXY)-ALKYL CARBAMATE DRUG CONJUGATES OF NAPROXEN AND PREGABALIN | Xgene Pharmaceutical Inc (KY) | 2023-08-16 | — | — | EP | claimed |
| CN-116507663-A | Method for producing polycarbonates using halogenated diaryl carbonates | 科思创德国股份有限公司 | 2023-07-28 | — | — | CN | claimed |
| WO-2022117472-A1 | PROCESS FOR PREPARING A POLYCARBONATE USING A HALOGENATED DIARYL CARBONATE | COVESTRO DEUTSCHLAND AG (DE) | 2022-06-09 | — | — | WO | claimed |
| EP-2951299-A1 | CYSTATHIONINE BETA-SYNTHASE ENZYME FOR TREATMENT OF HOMOCYSTINURIA | The Regents of The University of Colorado, A Body Corporate (US) | 2015-12-09 | — | — | EP | claimed |
| WO-2014120770-A1 | CYSTATHIONINE BETA-SYNTHASE ENZYME FOR TREATMENT OF HOMOCYSTINURIA | THE REGENTS OF UNIVERSITY OF COLORADO (US) | 2014-08-07 | — | — | WO | claimed |
| EP-1572728-B1 | POLYMER CONJUGATES WITH DECREASED ANTIGENICITY, METHODS OF PREPARATION AND USES THEREOF | MOUNTAIN VIEW PHARMACEUTICALS (US) | 2014-06-25 | — | — | EP | claimed |
| US-20120114742-A1 | Polymer Conjugates with Decreased Antigenicity, Methods of Preparation and Uses Thereof | MOUNTAIN VIEW PHARMACEUTICALS, INC. (US) | 2012-05-10 | — | — | US | claimed |
| US-20040062746-A1 | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof | MOUNTAIN VIEW PHARMACEUTICALS, INC. | 2004-04-01 | — | — | US | claimed |
| US-20040062748-A1 | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof | MOUNTAIN VIEW PHARMACEUTICALS, INC. | 2004-04-01 | — | — | US | claimed |
| WO-2003087190-A1 | METHOD OF PREPARING POLYESTERCARBONATES | GENERAL ELECTRIC COMPANY (US) | 2003-10-23 | — | — | WO | claimed |
| US-6600004-B1 | Preparing polyestercarbonates is presented in which a mixture of at least one activated diaryl carbonate is reacted under melt polymerization conditions with at least one aromatic dihydroxy compound together with at least one dicarboxylic | GENERAL ELECTRIC COMPANY | 2003-07-29 | — | — | US | claimed |
| US-6569985-B2 | Multistage; oligomerization using tetraalykyphosphorium catalyst and Group 1a hydroxide catalyst | GENERAL ELECTRIC COMPANY | 2003-05-27 | — | — | US | claimed |
| US-20030065129-A1 | Method for making polycarbonate | GENERAL ELECTRIC COMPANY | 2003-04-03 | — | — | US | claimed |
| WO-2003014188-A1 | METHOD FOR MAKING POLYCARBONATE | GENERAL ELECTRIC COMPANY (US) | 2003-02-20 | — | — | WO | claimed |
| US-20030012777-A1 | Polymer conjugates of proteinases | MOUNTAIN VIEW PHARMACEUTICALS, INC. | 2003-01-16 | — | — | US | claimed |
| WO-2003002716-A2 | POLYMER STABILIZED PROTEINASES | MOUNTAIN VIEW PHARMACEUTICALS, INC. (US) | 2003-01-09 | — | — | WO | claimed |
| US-6399739-B1 | PROCESS CONTROL USING COMPUTERS | GENERAL ELECTRIC COMPANY | 2002-06-04 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040062748-A1 | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof | CD14, HLA-C, HLA-A | FAAH 1966/4885ALDH1A1 3287/4885SMN1; SMN2 3522/4885 |
| US-20040062746-A1 | Polymer conjugates with decreased antigenicity, methods of preparation and uses thereof | CD14, HLA-C, HLA-A | FAAH 1966/4885ALDH1A1 3287/4885SMN1; SMN2 3522/4885 |
| US-20120114742-A1 | Polymer Conjugates with Decreased Antigenicity, Methods of Preparation and Uses Thereof | CD14, HLA-C, HLA-A | FAAH 1966/4885ALDH1A1 3287/4885SMN1; SMN2 3522/4885 |
| US-20030012777-A1 | Polymer conjugates of proteinases | PRNP, PRSS3, PRSS1 | FAAH 3421/4885ALDH1A1 2442/4885SMN1; SMN2 365/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.